Clinical Research Directory
Browse clinical research sites, groups, and studies.
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Sponsor: Minneapolis Heart Institute Foundation
Summary
The purpose of the research is to determine whether a class of medication called SGLT2 inhibitor will improve the heart's function and reduce its enlargement after a heart attack. Participation in this study will involve taking this class of medication (or a placebo) once daily for six months, one cardiac magnetic resonance imaging (MRI) test during your initial hospitalization, follow-up phone calls at 1 and 3 months, and one cardiac MRI and clinic visit at six months. This is a single center study.
Official title: Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition Improves Left Ventricular Function and Reduces Adverse Left-Ventricular Remodeling in High-Risk Patients with Microvascular Obstruction (MVO) Following ST-elevation Myocardial Infarction (STEMI).
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
81
Start Date
2022-08-03
Completion Date
2028-12
Last Updated
2024-10-08
Healthy Volunteers
No
Conditions
Interventions
SGLT-2 inhibitors
SGLT2 inhibitor once daily for six months
Placebo
Placebo once daily for six months
Locations (1)
Minneapolis Heart Institute Foundation
Minneapolis, Minnesota, United States